Uncategorized
Eylea co-formulated with rinucumab provided no more benefit than Eylea alone in wet AMD
Regeneron Pharmaceuticals announced that Eylea co-formulated with rinucumab provided no more benefit than Eylea alone in treating patients with neovascular age-related macular degeneration.In the phase 2 CAPELLA study, the combination therapy did not provide improvement in best corrected visual acuity outcomes in patients with neovascular AMD compared with those who received aflibercept alone, according to a press release. At 12-week follow-up, patients in the combination therapy cohort had a 5.8 letter improvement in BCVA, compared with a 7.5 letter improvement in BCVA in patients treated with aflibercept alone.